Amarin is cutting staff but others are hiring! Check it out! (Isn’t it tempting?)
Amarin Corp. (AMRN) said it will fire about half of its employees after a U.S. Food and Drug Administration advisory panel failed to back expanded use of its fish-oil pill Vascepa for those with high levels of fat in their blood. The panel voted 9-2 on Oct. 16 that Amarin should complete a study on the drug’s heart benefits before it is considered for the 36 million Americans with high triglyceride levels. The Dublin-based company said it is still evaluating its spending priorities and will consider other cost-cutting measures, including ongoing clinical trial expenses. It said it will give more details when it reports earnings next month.
Don’t forget, hundreds of biopharma companies are hiring! (We know you can’t resist.)
